In this way, activation of platelets by CD97 on tumor cells leads to a situation in which LPA is released from the platelets, giving the tumor cell more invasive properties, as a result of binding to a CD97-LPA receptor complex [46]. The gene discussed is ADGRE2; the disease is neoplasm.